OUR PIPELINE


LAST UPDATED: JANUARY 9, 2025

We are building a pipeline of *in vivo* and *ex vivo* therapies, as well as continuing to develop innovative modular platform capabilities.



IN VIVO PROGRAMS

IN VIVO CRISPR **is** the therapy **GENETIC DISEASES**



EX VIVO PROGRAMS

EX VIVO CRISPR **creates** the therapy IMMUNO-ONCOLOGY / AUTOIMMUNE DISEASE

PROGRAM	APPROACH	RESEARCH AND PRECLINICAL	EARLY-STAGE CLINICAL	LATE-STAGE CLINICAL	PARTNERS
Research Programs	Allogeneic and other				kyverna

Lead refers to lead development and commercial party.

* Intellia is advancing both wholly-owned and partnered programs.

** Nex-z (nexiguran ziclumeran), formerly known as NTLA-2001.

*** Hemophilia B is being advanced by Regeneron. Intellia is eligible for milestones and royalties.